Anticholinergic class drugs

9 results

  • Anoro ellipta

    (umeclidinium bromide and vilanterol trifenatate)
    GlaxoSmithKline LLC
    Usage: ANORO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or asthma treatment, and its safety and effectiveness in asthma have not been established.

  • Bevespi aerosphere

    (Glycopyrrolate and formoterol fumarate)
    AstraZeneca Pharmaceuticals LP
    Usage: BEVESPI AEROSPHERE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or for asthma treatment.

  • Cuvposa

    (glycopyrrolate)
    Merz Pharmaceuticals, LLC
    Usage: CUVPOSA is indicated for reducing chronic severe drooling in children aged 3 to 16 with neurologic conditions such as cerebral palsy.

  • Incruse ellipta

    (umeclidinium)
    GlaxoSmithKline LLC
    Usage: INCRUSE ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients.

  • Qbrexza

    (glycopyrronium)
    Journey Medical Corporation
    Usage: Qbrexza is indicated for the topical treatment of primary axillary hyperhidrosis in adults and pediatric patients aged 9 years and older.

  • Stiolto respimat

    (tiotropium bromide and olodaterol)
    Boehringer Ingelheim Pharmaceuticals Inc.
    Usage: STIOLTO RESPIMAT is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for acute COPD deteriorations or for the treatment of asthma.

  • Trelegy ellipta

    (fluticasone furoate, umeclidinium bromide and vilanterol trifenatate)
    GlaxoSmithKline LLC
    Usage: TRELEGY ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in patients aged 18 and older. It is not intended for the relief of acute bronchospasm.

  • Tudorza pressair

    (aclidinium bromide)
    AstraZeneca Pharmaceuticals LP
    Usage: TUDORZA® PRESSAIR® (aclidinium bromide) is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients.

  • Yupelri

    (revefenacin)
    Mylan Specialty L.P.
    Usage: YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).